Literature DB >> 16288370

Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.

Steven M Opal1, John E Palardy, Wilbur H Chen, Nicolas A Parejo, Apurba K Bhattacharjee, Alan S Cross.   

Abstract

BACKGROUND: An experimental vaccine for sepsis, composed of detoxified Escherichia coli J5 lipopolysaccharide (LPS) complexed with the outer membrane protein (OMP) of Neisseria meningitidis group B, induces anti-core glycolipid antibody and has been tested in pilot studies in human volunteers.
METHODS: Mice were immunized with the LPS-J5/OMP vaccine with or without synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs as a vaccine adjuvant (CpG ODN). The efficacy of the vaccine-induced antibody response was tested in a cecal ligation and puncture model.
RESULTS: Immunization resulted in a >20-fold increase in anti-core glycolipid antibody levels, which were further increased 5-fold by the addition of CpG ODN, compared with the levels in mice in the control group. The vaccine provided a survival advantage after a cecal ligation and puncture was performed (P < .01) and significantly decreased the levels of bacteria in organs. Immunoglobulin G (IgG) anti-core glycolipid antibodies were decreased in mice to a significantly greater extent than were levels of total circulating IgG or IgG to the OMP part of the vaccine complex, suggesting specific epitope binding and clearance.
CONCLUSIONS: These results indicate that the detoxified LPS-J5/OMP vaccine induces high levels of antibody against the core glycolipid of LPS and functions in vivo to promote clearance of gram-negative bacteria and improve the outcome of experimental polymicrobial intra-abdominal sepsis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288370     DOI: 10.1086/498167

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

Review 2.  Virulence and immunomodulatory roles of bacterial outer membrane vesicles.

Authors:  Terri N Ellis; Meta J Kuehn
Journal:  Microbiol Mol Biol Rev       Date:  2010-03       Impact factor: 11.056

3.  Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

Authors:  Alan S Cross; Nancy Greenberg; Melissa Billington; Lei Zhang; Christopher DeFilippi; Ryan C May; Kanwaldeep K Bajwa
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

4.  Top Down Tandem Mass Spectrometric Analysis of a Chemically Modified Rough-Type Lipopolysaccharide Vaccine Candidate.

Authors:  Benjamin L Oyler; Mohd M Khan; Donald F Smith; Erin M Harberts; David P A Kilgour; Robert K Ernst; Alan S Cross; David R Goodlett
Journal:  J Am Soc Mass Spectrom       Date:  2018-02-20       Impact factor: 3.109

5.  Lipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains.

Authors:  Maurílio F Santos; Roger R C New; Gabrielle R Andrade; Christiane Y Ozaki; Osvaldo A Sant'Anna; Lucia Mendonça-Previato; Luis R Trabulsi; Marta O Domingos
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

6.  The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis.

Authors:  Abdullah Chahin; Steven M Opal; Jorge Zorzopulos; David V Jobes; Yazan Migdady; Michelle Yamamoto; Nicholas Parejo; John E Palardy; David L Horn
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

7.  Enhanced antibody responses to a detoxified lipopolysaccharide-group B meningococcal outer membrane protein vaccine are due to synergistic engagement of Toll-like receptors.

Authors:  Wilbur H Chen; Subhendu Basu; Apurba K Bhattacharjee; Alan S Cross
Journal:  Innate Immun       Date:  2009-10-12       Impact factor: 2.680

8.  CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis.

Authors:  Girish Ramachandran; Raymond Kaempfer; Chun-Shiang Chung; Anat Shirvan; Abdullah B Chahin; John E Palardy; Nicolas A Parejo; Yaping Chen; Melissa Whitford; Gila Arad; Dalia Hillman; Ronen Shemesh; William Blackwelder; Alfred Ayala; Alan S Cross; Steven M Opal
Journal:  J Infect Dis       Date:  2014-10-09       Impact factor: 5.226

Review 9.  OMV Vaccines and the Role of TLR Agonists in Immune Response.

Authors:  Francesca Mancini; Omar Rossi; Francesca Necchi; Francesca Micoli
Journal:  Int J Mol Sci       Date:  2020-06-21       Impact factor: 5.923

Review 10.  Anti-endotoxin vaccines: back to the future.

Authors:  Alan S Cross
Journal:  Virulence       Date:  2013-08-13       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.